The Readout Loud

346 Odcinki

1. 342: FDA cuts, zombie biotechs, and too much weight loss?

   Opublikowany: 20.02.2025
2. 341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

   Opublikowany: 13.02.2025
3. 340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

   Opublikowany: 6.02.2025
4. 339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

   Opublikowany: 30.01.2025
5. 338: Chinese biotechs, a WHO departure, and post-JPM thoughts

   Opublikowany: 23.01.2025
6. 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

   Opublikowany: 15.01.2025
7. 336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

   Opublikowany: 9.01.2025
8. 335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

   Opublikowany: 19.12.2024
9. 334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

   Opublikowany: 12.12.2024
10. 333: An H5N1 bird flu update and talent scarcity in the radiopharma field

    Opublikowany: 5.12.2024
11. 332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

    Opublikowany: 21.11.2024
12. 331: AbbVie’s stumble, Amgen’s tumble and more election fallout

    Opublikowany: 14.11.2024
13. 330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

    Opublikowany: 7.11.2024
14. 329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

    Opublikowany: 31.10.2024
15. 328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

    Opublikowany: 24.10.2024
16. 327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

    Opublikowany: 17.10.2024
17. 326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

    Opublikowany: 10.10.2024
18. 325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

    Opublikowany: 3.10.2024
19. From Tradeoffs: Race to the Bottom

    Opublikowany: 28.09.2024
20. 324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

    Opublikowany: 26.09.2024